| Writing Group Member | Employment | Research Grant | Other Research Support | Speakers' Bureau/Honoraria | Ownership Interest | Consultant/Advisory Board | Other |
|---|---|---|---|---|---|---|---|
| Gregory J. del Zoppo | University of Washington | none | none | none | none | none | none |
| Harold P. Adams, Jr | University of Iowa | Grant to University of Iowa to provide continuing medical education on management of acute stroke (Genentech)* | None | Optum Health* (lecture on emergency treatment of stroke); National Stroke Association* (developed educational program for stroke care) | None | None | None |
| Edward C. Jauch | Medical University of South Carolina | NIH grant (IMS3 Trial-Study Executive Committee)† | Novo Nordisk* | None | None | Genentech* | None |
| Jeffrey L. Saver | University of California at Los Angeles | Boehringer Ingelheim* | Concentric* | Concentric Medical*; Boehringer Ingelheim*; Ferrer* | None | CoAxia*; Talecris*; ev3*; Ferrer*; Concentric Medical*; Cygnis* | NIH* (IMS3 Trial and CLEAR Trial) |
| This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit A relationship is considered to be “significant” if (1) the person receives $10 000 or more during any 12-month period, or 5% or more of the person's gross income; or (2) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition. | |||||||
| * Modest. | |||||||
| † Significant. |